ClinicalTrials.gg
CompletedNCT01890785Updated Jun 3, 2021Results posted

Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers

A Phase 1 interventional study of Lisdexamfetamine Dimesylate in Healthy Volunteers, sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Compare the pharmacokinetic profiles when the contents are emptied into a soft food and orange juice compared to the SPD489 when swallowed as an intact capsule.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.

Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.

First submitted before Shire became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-55 years inclusive at the time of consent. The date of signing is defined as the beginning of the Screening Period. This inclusion criterion will only be assessed at the first screening visit.
  2. Willingness to comply with any applicable requirements fo the protocol and is:

    • Male, or
    • Non pregnant, non lactating female
    • Females must be at least 90 days post partum or nulliparous
  3. Must be considered "healthy". Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead , hematology, blood chemistry, and urinalysis.
  4. An understanding, ability, and willingness to fully comply with study procedures and restrictions
  5. Ability to provide written, personally signed, and dated informed consent to participate in the study, in accordance with International Conference on harmonisation Good Clinical Practice Guideline E6 (1996) and applicable regulations, before completing any study related procedures
  6. A between 18.5-30.0kg/m² inclusive. This inclusion criterion will only be assessed at the first screening visit.
  7. A value of >=12.0g/dL at the Screening Visit and on Day -1 of Treatment Period 1.
  8. Ability to swallow a dose of product according to the study conditions.

Exclusion criteria

Exclusion Criteria:

Subjects are excluded from the study if any of the following criteria are met at the Screening Visit or at Day 1 of Treatment Period 1 (if reassessed):

  1. Current or recurrent disease (eg, cardiovascular, renal, liver, gastrointestinal, , or other conditions) that could affect the action, absorption, or disposition of the products, or could affect clinical or laboratory assessments.
  2. Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures.
  3. Significant illness, as judged by the investigator, within 2 weeks of the first dose of investigational product.
  4. History of significant anxiety, tension, or agitation as assessed by the investigator.
  5. History of or current diagnosis of glaucoma.
  6. History of a seizure disorder (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or known family history of Tourette's Disorder.
  7. History or presence of known structural cardiac abnormalities, syncope, cardiac conduction problems, exercise-related cardiac events, or bradycardia.
  8. History of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or stroke or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
  9. History of controlled or uncontrolled hypertension or a resting supine systolic blood pressure >139mmHg or diastolic blood pressure >89mmHg.
  10. Known family history of sudden cardiac death or ventricular arrhythmia.
  11. Currently considered a suicide risk, has previously made a suicide attempt, or has a history of, or is currently demonstrating suicidal ideation.
  12. Current use of any medication (including prescription, over-the-counter, herbal or homeopathic preparations) with the exception of hormonal replacement therapy or hormonal (current use is defined as use within 14 days of first dose of investigational product).
  13. Use of any medication known to inhibit or induce the cytochrome P450 (CYP450) enzymes responsible for the metabolism of the investigational product within 14 days of first dose of investigational product.
  14. Known or suspected intolerance or to the investigational product, closely related compounds, or any of the stated ingredients.
  15. Known or suspected intolerance or hypersensitivity to orange juice or vanilla yogurt.
  16. History of alcohol or other substance abuse within the last year.
  17. A positive screen for alcohol or drugs of abuse at the Screening Visit or on Day 1 of Treatment Period 1.
  18. Male subjects who consume more than 3 units of alcohol per day. Female subjects who consume more than 2 units of alcohol per day. (1 alcohol unit=1 beer=1 wine [5oz]=one liquor [1.5 oz]=0.75oz alcohol.).
  19. A positive antibody screen, surface antigen, or virus antibody screen.
  20. Use of tobacco in any form (eg, smoking or chewing) or other nicotine-containing products in any form (eg, gum, patch) within 30 days prior to the first dose of investigational product.
  21. Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches or have a history of caffeine withdrawal headaches. (One caffeine unit is contained in the following items: one 6oz cup of coffee, two 12oz cans of cola, one 12oz cup of tea, three 1oz chocolate bars. Decaffeinated coffee, tea, or cola are not considered to contain caffeine).
  22. Donation of blood or blood products (eg, plasma or ) within 60 days prior to the first dose of investigational product.
  23. Use of another investigational product within 30 days prior to receiving the first dose of investigational product or active enrollment in another drug or vaccine clinical study.
  24. Substantial changes in eating habits within 30 days prior to receiving the first dose of investigational product, as assessed by the investigator.
  25. An inability to follow a standardized diet and meal schedule or inability to fast, as required during the study.
  26. Prior screen failure, randomization, participation, or enrollment in this study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Lisdexamfetamine Dimesylate Fasting

    lisdexamfetamine dimesylate 70 mg capsule administered under fasted conditions

    Drug: Lisdexamfetamine Dimesylate

  • Experimental
    Lisdexamfetamine Dimesylate Vanilla Yogurt

    Lisdexamfetamine Dimesylate 70mg capsule mixed into vanilla yogurt

    Drug: Lisdexamfetamine Dimesylate

  • Experimental
    Lisdexamfetamine Dimesylate Orange Juice

    Lisdexamfetamine Dimesylate 70mg capsule mixed into orange juice

    Drug: Lisdexamfetamine Dimesylate

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve (AUC) for Lisdexamfetamine Dimesylate

    AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

    Time frame: Up to 96 hours post-dose

  2. Maximum Plasma Concentration (Cmax) for Lisdexamfetamine Dimesylate

    Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

    Time frame: Up to 96 hours post-dose

  3. AUC for D-amphetamine

    d-Amphetamine is a metabolite of Lisdexamfetamine Dimesylate and is an active form that is responsible for the drug's therapeutic activity.

    Time frame: Up to 96 hours post-dose

  4. Cmax for D-amphetamine

    d-Amphetamine is a metabolite of Lisdexamfetamine Dimesylate and is an active form that is responsible for the drug's therapeutic activity.

    Time frame: Up to 96 hours-post-dose

07

Results

Posted Apr 21, 2014

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6
Started555555
Completed555555
Not completed000000
Second Intervention
Participant flow — Second Intervention
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6
Started555555
Completed555555
Not completed000000
Third Intervention
Participant flow — Third Intervention
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6
Started555555
Completed545555
Not completed010000
Withdrew: Withdrawal by subject010000

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve (AUC) for Lisdexamfetamine Dimesylate

AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

Time frame:
Up to 96 hours post-dose
Reported as:
Mean · ng*hr/ml
Area Under the Plasma Concentration-time Curve (AUC) for Lisdexamfetamine Dimesylate
ng*hr/mlLisdexamfetamine Dimesylate Mixed in Orange JuiceLisdexamfetamine Dimesylate Mixed in Vanilla YogurtLisdexamfetamine Dimesylate Intact Capsule Fasting
Area Under the Plasma Concentration-time Curve (AUC) for Lisdexamfetamine Dimesylate27.0 ± 7.836.0 ± 14.238.3 ± 12.3
Statistical analysis
  • Lisdexamfetamine Dimesylate Mixed in Orange Juice vs Lisdexamfetamine Dimesylate Intact Capsule Fasting · Ratio of geometric least squares means: 0.708 · 90% CI 0.655 to 0.766
  • Lisdexamfetamine Dimesylate Mixed in Vanilla Yogurt vs Lisdexamfetamine Dimesylate Intact Capsule Fasting · Ratio of geometric least squares means: 0.918 · 90% CI 0.849 to 0.992
PrimaryMaximum Plasma Concentration (Cmax) for Lisdexamfetamine Dimesylate

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

Time frame:
Up to 96 hours post-dose
Reported as:
Mean · ng/ml
Maximum Plasma Concentration (Cmax) for Lisdexamfetamine Dimesylate
ng/mlLisdexamfetamine Dimesylate Mixed in Orange JuiceLisdexamfetamine Dimesylate Mixed in Vanilla YogurtLisdexamfetamine Dimesylate Intact Capsule Fasting
Maximum Plasma Concentration (Cmax) for Lisdexamfetamine Dimesylate24.5 ± 7.4832.2 ± 11.4638.5 ± 13.07
Statistical analysis
  • Lisdexamfetamine Dimesylate Mixed in Orange Juice vs Lisdexamfetamine Dimesylate Intact Capsule Fasting · Ratio of geometric least squares means: 0.641 · 90% CI 0.582 to 0.707
  • Lisdexamfetamine Dimesylate Mixed in Vanilla Yogurt vs Lisdexamfetamine Dimesylate Intact Capsule Fasting · Ratio of geometric least squares means: 0.828 · 90% CI 0.752 to 0.912
PrimaryAUC for D-amphetamine

d-Amphetamine is a metabolite of Lisdexamfetamine Dimesylate and is an active form that is responsible for the drug's therapeutic activity.

Time frame:
Up to 96 hours post-dose
Reported as:
Mean · ng*h/ml
AUC for D-amphetamine
ng*h/mlLisdexamfetamine Dimesylate Mixed in Orange JuiceLisdexamfetamine Dimesylate Mixed in Vanilla YogurtLisdexamfetamine Dimesylate Intact Capsule Fasting
AUC for D-amphetamine1140.9 ± 274.11110.1 ± 252.91180.2 ± 295.1
Statistical analysis
  • Lisdexamfetamine Dimesylate Mixed in Orange Juice vs Lisdexamfetamine Dimesylate Intact Capsule Fasting · Ratio of geometric least squares means: 0.970 · 90% CI 0.937 to 1.004
  • Lisdexamfetamine Dimesylate Mixed in Vanilla Yogurt vs Lisdexamfetamine Dimesylate Intact Capsule Fasting · Ratio of geometric least squares means: 0.944 · 90% CI 0.912 to 0.977
PrimaryCmax for D-amphetamine

d-Amphetamine is a metabolite of Lisdexamfetamine Dimesylate and is an active form that is responsible for the drug's therapeutic activity.

Time frame:
Up to 96 hours-post-dose
Reported as:
Mean · ng/ml
Cmax for D-amphetamine
ng/mlLisdexamfetamine Dimesylate Mixed in Orange JuiceLisdexamfetamine Dimesylate Mixed in Vanilla YogurtLisdexamfetamine Dimesylate Intact Capsule Fasting
Cmax for D-amphetamine59.1 ± 9.4759.0 ± 9.2861.0 ± 10.81
Statistical analysis
  • Lisdexamfetamine Dimesylate Mixed in Orange Juice vs Lisdexamfetamine Dimesylate Intact Capsule Fasting · Ratio of geometric least squares means: 0.971 · 90% CI 0.945 to 0.998
  • Lisdexamfetamine Dimesylate Mixed in Vanilla Yogurt vs Lisdexamfetamine Dimesylate Intact Capsule Fasting · Ratio of geometric least squares means: 0.970 · 90% CI 0.944 to 0.997

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lisdexamfetamine Dimesylate Mixed in Orange Juice—0/30 (0%)16/30 (53.3%)
Lisdexamfetamine Dimesylate Mixed in Vanilla Yogurt—0/30 (0%)17/30 (56.7%)
Lisdexamfetamine Dimesylate Intact Capsule Fasting—0/30 (0%)9/30 (30%)
Most frequent other events
Most frequent other events
EventLisdexamfetamine Dimesylate Mixed in Orange JuiceLisdexamfetamine Dimesylate Mixed in Vanilla YogurtLisdexamfetamine Dimesylate Intact Capsule Fasting
Decreased appetiteMetabolism and nutrition disorders9/308/303/30
Dry mouthGastrointestinal disorders3/305/303/30
HeadacheNervous system disorders4/303/304/30
DizzinessNervous system disorders1/302/301/30
Psychomotor hyperactivityNervous system disorders1/302/301/30
AnxietyPsychiatric disorders0/300/302/30

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Total
Mean32.6 ± 10.1635.4 ± 12.4242.2 ± 4.4434.2 ± 12.4239.6 ± 9.8641.8 ± 10.0637.6 ± 10.07
Age, Customized
Age, Customized(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Total
Between 18 and 65 years, inclusive55555530
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Total
Female1210228
Male43453322
Region of Enrollment
Region of Enrollment(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Total
UNITED STATES55555530
08

Study locations

1 site
  • Clinical Pharmacology of Miami, Inc
    Miami, Florida, United States
09

References and documents

Publications

  • Ermer J, Corcoran M, Lasseter K, Martin PT. Relative Bioavailabilities of Lisdexamfetamine Dimesylate and D-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink. Ther Drug Monit. 2016 Dec;38(6):769-776. doi: 10.1097/FTD.0000000000000343. PubMed 27661399 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2013 to primary completion in Aug 2013, 1 month.

Results were first posted in Apr 2014, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2013
First posted
Jul 2, 2013
StartActual
Jul 15, 2013
Primary completionActual
Aug 22, 2013
CompletionActual
Aug 22, 2013
Results first posted
Apr 21, 2014
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01890785
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jul 2, 2013
Start date
Jul 15, 2013
Primary completion
Aug 22, 2013
Completion
Aug 22, 2013
Results posted
Apr 21, 2014
Last update
Jun 3, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion